Quote Request
Humanized Mouse Models for Pancreatic Cancer
Humanized mouse models are an innovative tool in biomedical research, specifically designed to study human diseases, including cancer. At Alfa Cytology, we leverage our profound expertise and state-of-the-art technology to craft a robust and reproducible drug-resistant model as a valuable tool for delving into tumor genesis, progression, and therapy response.
The Challenge of Pancreatic Cancer Model Development
The unique biology of pancreatic cancer, including its diverse cell types and complex tumor microenvironment, poses challenges that traditional mouse models often fail to mimic human body accurately. Humanized mouse models fill this gap by closely simulating human disease pathology and immune interactions.
Fig. 1 Different mouse models to study oncoimmunology. (Horowitz NB., et al., 2021)
Humanized Mouse Models for Pancreatic Cancer
Humanized mouse models are created by engrafting human cells or tissues into immunocompromised mice, allowing researchers to investigate human-specific biological processes, immune responses, and therapeutic effects in a living organism. In pancreatic cancer, humanized mouse models provide invaluable insights into tumor biology, treatment responses, and the interaction between human tumors and the immune system.
| Advantages of Humanized Mouse Models | |
|---|---|
| Enhanced Human Immune Response | Humanized mice contain human immune cells, allowing researchers to study how the human immune system interacts with pancreatic tumors. This is crucial for developing immunotherapies that can effectively harness the patient's immune response to fight cancer. |
| Better Tumor Microenvironment Representation | These models can incorporate human stromal cells, which contribute to the tumor microenvironment, providing a more accurate representation of how pancreatic tumors develop, progress, and respond to treatments. |
| Personalized Medicine Development | Researchers can develop personalized models to test specific therapies tailored to individual patients by using patient-derived tumor samples and engrafting them into humanized mice. This approach holds great promise for enhancing treatment efficacy and reducing adverse effects. |
| Evaluation of Combination Therapies | Humanized mouse models allow for the testing of both traditional chemotherapeutics and novel immunotherapies in combination. This can lead to the identification of synergistic treatments that improve patient outcomes. |
Our Services
Humanized mouse models represent a pivotal advancement in the study of pancreatic cancer, facilitating a deeper understanding of tumor biology and immune dynamics. recognizes the pivotal role of developing drug resistance models in pancreatic cancer to decipher resistance mechanisms and unearth efficacious therapeutic avenues. By amalgamating experimental models with cutting-edge technologies, Alfa Cytology aims to overcome immunological problems by humanizing mouse models of pancreatic cancer.
Workflow of Humanized Mouse Models Development
Through a comprehensive sequence of steps, we tailor a mouse model of pancreatic cancer that mirrors the body's drug resistance, shedding light on the intricacies of drug resistance in this context. This model serves as a springboard for the identification of novel therapeutic targets and the formulation of effective strategies to combat drug resistance in pancreatic cancer.
Selection of Immunocompromised Strains
Immunocompromised mouse strains lack key immune components, allowing for the survival and proliferation of human cells without rejection. Humanized mouse models can be created using a variety of human cell types.
Engraftment of Human Cells
Human hematopoietic stem cells (HSCs) are infused into the mice, allowing for the repopulation of the mouse immune system with human immune cells. Additionally, patient-derived pancreatic tumor tissues are implanted to study the interaction between the human immune cells and the tumor microenvironment.
Validation of Humanization
Once the engraftment is successful, researchers validate the extent of humanization by analyzing the presence and functionality of human immune cells in the mouse model. This ensures that the model accurately reflects human immune responses.
Therapeutic Testing and Research
With a fully humanized immune system and pancreatic tumor, researchers can begin testing various therapeutic agents and combinations, evaluating their efficacy, immune interactions, and potential side effects.
Applications of Humanized Mouse Models for Pancreatic Cancer
- Immunotherapy Studies - Humanized mouse models are an excellent platform for investigating novel immunotherapeutic approaches, including checkpoint inhibitors and CAR T-cell therapies, providing insights into their mechanisms of action and potential effectiveness in pancreatic cancer.
- Understanding Tumor-Immune Interactions - Researchers can explore how pancreatic tumors interact with the human immune system, examining factors contributing to immune evasion and resistance to therapies.
- Preclinical Drug Development - Humanized models enable the preclinical evaluation of new drugs and combination therapies, accelerating the drug development process and improving the chances of successful clinical trials.
- Biomarker Discovery - Researchers can identify potential biomarkers that predict therapy efficacy in pancreatic cancer by analyzing response patterns in treated humanized mice.
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
Case Study - Bxpc-3 HuPBMC C-NKG Mouse Model
- Model Introduction
The orthotopic pancreatic cancer model in huPBMC C-NKG mice provides a sophisticated and clinically relevant platform for evaluating human-specific immunotherapies against pancreatic ductal adenocarcinoma (PDAC). This model uniquely combines an orthotopic tumor implantation site with a functional human immune system, enabling the study of tumor-immune interactions, metastatic progression, and the efficacy of checkpoint inhibitors or other immunomodulatory agents in a humanized context.
- Model Information
- Model: Bxpc-3 HuPBMC C-NKG Mouse Model
- Animals: C-NKG Mice
- Age: 6-8 Weeks
- Cancer Type: Adenocarcinoma
- Weight: 18-22 g
- Model Construction
The orthotopic pancreatic cancer model in huPBMC-C-NKG mice is specifically designed for preclinical evaluation of human-specific immunotherapies. The model is established through a sequential two-phase construction protocol to ensure proper human immune system engraftment prior to tumor challenge.
- Human Immune System Reconstitution Phase: 6-8 week old C-NKG immunodeficient mice receive intravenous injection of 5-10×10⁶ human peripheral blood mononuclear cells (huPBMC) from healthy donors. Engraftment is monitored for 2-3 weeks to achieve stable human T-cell levels (>25% hCD45+ in peripheral blood).
- Subcutaneous Tumor Implantation Phase: Following successful immune reconstitution, a suspension of human pancreatic cancer Bxpc-3 cells (typically 1-2×10⁶ cells in matrigel) is injected subcutaneously into the right flank of engrafted mice.
Fig. 2 Workflow of Bxpc-3 HuPBMC C-NKG mice model establishment. (Source: Alfa Cytology)
- Model Data
- Human Immune Reconstitution: Three weeks after PBMC transplantation, the proportion of human leukocytes (hCD45+) in the peripheral blood of C-NKG mice reached an average of 50%, with T cells predominating in the reconstitution.
- GvHD Response: Graft-versus-host disease (GVHD) began to appear approximately 28 days post-transplantation, manifested as a significant decrease in body weight. After 45 days, the weight loss in mice generally exceeded 20%.
Fig. 3 Changes in the population of human CD45+ and CD3+ cells in the peripheral blood of C-NKG mice following human PBMC transplantation. Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
- Subcutaneous Implantation: On day 7 post-implantation, the tumor volume reached 100-200 mm3 and progressed to the endpoint volume of 1400 mm3 by day 28. A single dose of Pembrolizumab administered during the therapeutic intervention window significantly inhibited tumor growth and reduced tumor volume.
Fig. 4 Tumor volume growth curve of pancreatic cancer Bxpc-3 cells subcutaneous transplantation (n=6). Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
Future advancements in humanized mouse models will focus on improving the complexity of the tumor microenvironment, incorporating additional human cell types, and enhancing the mimicry of authentic human immune responses. Continuous technological innovations and a deeper understanding of pancreatic cancer biology will contribute to the evolution of these models, ultimately enhancing their applicability in clinical research. If you are interested in our drug resistance model development services, please contact us for more details. You can contact our staff directly and receive professional, reliable, and fast feedback.
Reference
- Horowitz NB, et al. Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies. Front Immunol. 2021;12:648580. Published 2021 Apr 22. doi:10.3389/fimmu.2021.648580
